CRH Names Alan Connolly Interim CFO-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CRH Names Alan Connolly Interim CFO

Dec 6, 2024 5:00 AM

07:30 AM EST, 12/06/2024 (MT Newswires) -- CRH (CRH) said Friday it has named Alan Connolly interim chief financial officer, effective Jan. 1.

Connolly will succeed current CFO Jim Mintern, who will assume the chief executive role, the company said.

Connolly was previously the director of strategic finance, said CRH, which is actively searching for a permanent successor.

Previous page： Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares Next page： Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares

Nov 7, 2025

08:34 AM EST, 11/07/2025 (MT Newswires) -- Strategy (MSTR) said Friday it priced an initial public offering a day earlier of about 7.8 million shares of 10% series A perpetual preferred stock at 80 euros ($92.48) each. The issuance and sale of the stock under the ticker STRE is scheduled to settle on Nov. 13, the company said. Strategy said...

Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug

Nov 7, 2025

08:34 AM EST, 11/07/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that new long-term data on its drug Livdelzi showed consistent efficacy and safety in treating primary biliary cholangitis, including in patients who switched from obeticholic acid, with sustained improvements in liver stiffness over three years. The company said the long-term study showed that 67% of participants...

Boralex Q3 Loss Widens on Weak Power Prices Despite Higher Output

Nov 7, 2025

08:34 AM EST, 11/07/2025 (MT Newswires) -- Boralex ( BRLXF ) on Friday said its third-quarter loss widened as revenue fell as weaker prices offset higher power production. The renewable-power company said it lost $27 million, or $0.26 per share, compared to a loss of $14 million, or $0.13, in the year-prior quarter. The result lagged the FactSet consensus estimate...

Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study

Nov 7, 2025

08:34 AM EST, 11/07/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that Dupixent (dupilumab) for treatment of allergic fungal rhinosinusitis in adults and children aged six years and older met all primary and secondary endpoints in a phase three study. The study showed that Dupixent significantly reduced key nasal signs and symptoms...